GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SciSparc Ltd (OTCPK:SPRCY) » Definitions » LT-Debt-to-Total-Asset

SciSparc (SciSparc) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is SciSparc LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. SciSparc's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

SciSparc's long-term debt to total assets ratio increased from Dec. 2022 (0.00) to Dec. 2023 (0.00). It may suggest that SciSparc is progressively becoming more dependent on debt to grow their business.


SciSparc LT-Debt-to-Total-Asset Historical Data

The historical data trend for SciSparc's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciSparc LT-Debt-to-Total-Asset Chart

SciSparc Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 - - - -

SciSparc Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

SciSparc LT-Debt-to-Total-Asset Calculation

SciSparc's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.024/11.182
=0.00

SciSparc's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.024/11.182
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SciSparc  (OTCPK:SPRCY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


SciSparc LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of SciSparc's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


SciSparc (SciSparc) Business Description

Traded in Other Exchanges
Address
20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.